A Pharmacokinetic (PK) Trial in Healthy Asian and Caucasian Volunteers Investigating the PK Profile of Eurartesim™

sigma-tau i.f.r. S.p.A.80 enrolled

Overview

The Study was designed to evaluate the pharmacokinetics of DHA and PQ in healthy volunteers and to assess the effect of ethnicity (Asian vs Caucasian), gender and body weight on the relative bioavailability of DHA and PQ.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Malaria, Falciparum

Interventions

EurartesimDRUG

Tablet containing 40 mg of Dihydroartemisinin (DHA) and 320 mg of Piperaquine phosphate (PQP). 3 Tablets a Day for body weight comprised between 36 and 75 kg, 4 tablets for body weight above 75 kg.

Eligibility

Sex: ALLMin age: 18 YearsMax age: 50 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Caucasian or Asian healthy subjects, Male or female, aged between 18 and 50 years (inclusive) * Body Mass Index (BMI) between 19.0 kg/m2 and 27.0 kg/m2 inclusive, with a minimum body weight of 36 kg. * Agreed to use two approved methods of contraception * Had given written informed consent to participate in this study in accordance with local regulations Exclusion Criteria: * Had received or was anticipated to receive a prescription medication within 14 days prior to the start of dosing * Pregnant or lactating (females only) * Abnormal laboratory test results deemed clinically significant at screening * Positive urine drug test or alcohol breath test * Acute therapy for a serious infection within 30 days of study entry * History of significant drug allergies or significant allergic reactions * Had participated in a clinical trial or had received an experimental therapy within 30 days or 10 half-lives of the drug * Receipt of blood or blood products, or loss or donation of 450 mL or more of blood within 90 days before the first dose administration

Locations (2)

CMAX, a division of IDT Australia Limited

Adelaide, Australia

Nucleus Network Limited

Melbourne, Australia

Outcomes

Primary Outcomes

PK: tmax, Cmax, AUC0-12(DHA), AUC0-24(PQ), AUC0-inf, λz, t1/2

DHA evaluation: At pre-dose on day Day 0 and Day 2 and then at 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, and 12 hours post-dose. PQ evaluation: At pre-dose Day 0 and then at 1, 2, 3, 4, 5, 6, 8, 12, and 16 hours post-dose; then at pre-dose Day 1 and Day 2 and finally at 1, 2, 3, 4, 5, 6, 8, 12, and 16 hours post-dose on day 2; on Day 3, 4, 5, 7, 14, 21, 28, 42, 56 and 90.

Time frame: During the first and last day of drug administration (day 0 and 2) and followed up till Day 90

Secondary Outcomes

Number of Treatment Emergent Adverse Events (TEAEs)

Number of TEAEs and number of Subjects experiencing Adverse Events during all the study period

Time frame: From Day 0 till Day 90

Hematology and blood chemistry changes respect to baseline values

Abnormalities in hematology (Haemoglobin, Hematocrit,RBC count, White cell count and differential count, Platelets) and clinical chemistry (Protein, Sodium, Potassium, Chloride ,Total Bilirubin, Conjugated Bilirubin, Alanine Aminotransferase, Aspartate Aminotransferase, Total Cholesterol, Glucose, Bicarbonate, Urea, Urate, Lactate Dehydrogenase, Albumin, Globulins, Triglycerides, Creatinine, Alkaline Phosphatase, Gamma glutamyltransferase, Total Calcium, Phosphate, C-reactive protein) will be recorded the day of the last study drug intake and after 30 days from the start of the drug treatment

Time frame: Day 0, Day 3, Day 28, Day 90

QTc interval prolongation

ECG recordings will be obtained at baseline, after the last drug intake and 30 days follow-up to investigate changes in ECG parameters, and specifically QTc interval changes respect to baseline

Time frame: Day 0, day 3, day 28, day 90

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.